Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

BioAge Labs (BIOA) Change in Accured Expenses (2023 - 2026)

BioAge Labs' Change in Accured Expenses history spans 2 years, with the latest figure at $1.4 million for Q4 2025.

On a quarterly basis, Change in Accured Expenses fell 38.71% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.4 million, a 173.73% decrease, with the full-year FY2025 number at -$3.4 million, down 173.73% from a year prior.
Change in Accured Expenses hit $1.4 million in Q4 2025 for BioAge Labs, up from -$542000.0 in the prior quarter.
Over the last five years, Change in Accured Expenses for BIOA hit a ceiling of $8.2 million in Q3 2024 and a floor of -$6.9 million in Q1 2025.